Dr Rob van Montfort studies target-directed cancer drug discovery, focusing on protein-ligand interactions, using protein crystallography and a range of biochemical and biophysical methods.

He leads the Hit Discovery and Structural Design Team within the Cancer Research UK Cancer Therapeutics Unit (CTU) at the ICR. The Team is composed of the Analytical Technology and Screening and Structure-Based Design groups, and is responsible for hit identification and characterisation of advanced inhibitors resulting from the drug discovery projects of the CTU.